hrp0092p1-30 | Diabetes and Insulin | ESPE2019

Effects of Glypican-4 Protein on INS1E Cell Viability and Insulin Signalling

Buhl Joseph , Garten Antje , Richter Sandy , Kiess Wieland , Penke Melanie

Background: Glypican-4 is a heparan sulphate proteoglycan. In addition to a membrane-bound glypican-4, a soluble form exists. Human and rodent adipose tissue were identified as source of circulating glypican-4. Glypican-4 serum levels are associated with obesity and insulin resistance, as in type 2 diabetes (T2D). Because of its positive effect on insulin sensitivity, glypican-4 might play a role in the development of obesity, insulin resistance, and T2D. We a...

hrp0089p3-p375 | Thyroid P3 | ESPE2018

Congenital Hypothyroidism – Diagnose Early and Keep Going

Sergeyev Elena , Sloltze Anette , Kiess Wieland , Pfaeffle Roland , Koerner Antje

Background: Serious mental and physical retardation are sequelae of untreated congenital hypothyroidism. These complications have become rare since the introduction of neonatal screening in Germany.Case report: Here we report about a girl with congenital hypothyroidism, who suffered from extreme short and thickset stature, rough facial features and straw-like hair at the age of 12 years. She had been detected in newborn screening with a TSH of 132 IU/ml....

hrp0086p1-p232 | Diabetes P1 | ESPE2016

Extrahepatic Biliary Atresia in Combination with Toxic Cholestasis Due to Glibenclamide in a Case of Neonatal Diabetes

Kapellen Thomas , Flemming Gunter , Bartelt Heike , Wachowiak Robin , Kiess Wieland

Background: More than 20 gene loci are known to cause monogenic neonatal diabetes today. A definite mutation can be found in 65–70% of all cases. Mutations in the ATP sensitive potassium channel can frequently be treated by sulfonylurea. Glibenclamide is on of the drugs known to inhibit the bile salt export pump (BSEP). However most drug induced cholestasis cases are reported in adults.Objective and hypotheses: Glibenclamide is used frequently to tr...

hrp0094fc2.4 | Fat, Metabolism and Obesity | ESPE2021

PTEN germline mutations lead to adipose tissue overgrowth mediated via FOXO1 and SREBP1.

Kirstein Anna , Kehr Stephanie , Nebe Michele , Kiess Wieland , Garten Antje ,

Background and Aim: Pediatric patients with germline mutations in the tumor suppressor gene PTEN (PTEN hamartoma tumor syndrome, PHTS) frequently develop lipomas. PTEN antagonizes phosphoinositide 3-kinase (PI3K) signaling, which can induce adipogenesis upon activation through insulin. The PI3K downstream target AKT can deactivate FOXO1 via phosphorylation, initiating the expression of the lipogenesis activating transcription factor SREBP1. To study t...

hrp0086p2-p877 | Syndromes: Mechanisms and Management P2 | ESPE2016

Pituitary Gigantism and Central Precocious Puberty Presenting with Prognathism in a Pediatric Patient

Minutti Carla , Idrovo Alexandra

Case Report: A 13-year old male presented to a dental office for evaluation of prognathism. After evaluation, his dentist referred him to pediatric endocrinology. He had no significant past medical history. He denied any signs or symptoms associated with any hormonal deficit or excess, as well as headaches or visual disturbances. Denied excessive growth of hands or feet. Parents reported that he had been having pubic and axillary hair, mild acne, and significant growth for the...

hrp0084p3-944 | GH & IGF | ESPE2015

The Impact of GH Therapy in Noonan Syndrome Children with Identified Mutations in RAS/MAPK Pathway

Malaquias Alexsandra , Moraes Michelle , Funari Mariana , Pereira Alexandre , Bertola Debora , Jorge Alexander

Objective: To evaluate the response to recombinant human GH (rhGH) treatment in NS children with short stature and previously identified mutations in the RAS/MAPK pathway genes.Methods: 23 patients with NS (17 males; 19 PTPN11, 3 RAF1 e 1 SHOC2) were daily treated with rhGH (mean rhGH dose of 47 μg/kg per day). The main outcome measures were 1st year growth velocity, change in height SDS (Noonan syndrome specifi...

hrp0095p1-263 | Fat, Metabolism and Obesity | ESPE2022

Small integral membrane protein 10 like 1 (SMIM10L1) affects adipogenesis and apoptosis in adipose progenitor cells.

Kirstein Anna , Nebe Michèle , Richter Sandy , Kiess Wieland , Garten Antje

Background: Pediatric patients with germline pathogenic variants in the tumor suppressor gene PTEN frequently develop cancer and adipose tissue overgrowth in the form of lipomas. While the canonical function of the phosphatase PTEN is to antagonize the growth promoting PI3K pathway, non-canonical PTEN functions e.g. in the nucleus are less well described. To uncover the mechanisms leading to lipoma formation related to PTEN mutations, we previously performed R...

hrp0092fc4.2 | Fat Metabolism and Obesity Session | ESPE2019

Characterization of the Adipose Progenitor Cell Marker MSCA1 in Normal Weight and Obese Children

Hanschkow Martha , Bouloumié Anne , Dietrich Arne , Kiess Wieland , Körner Antje , Landgraf Kathrin

Background: Obesity is characterized by an increase in fat mass caused by an increase in adipocyte number and adipocyte size and is often associated with adipose tissue (AT) dysfunction contributing to metabolic impairment. It is suspected that adipocyte progenitor cells play an important role during healthy and obesity-related AT expansion. Studies in adults showed that the stroma vascular fraction (SVF) of AT is composed of different progenitor cell subpopul...

hrp0092p2-110 | Fat, Metabolism and Obesity | ESPE2019

Pubertal Milestones and Related Hormonal Changes Among Children with Obesity

Stein Robert , Kempf Elena , Gesing Julia , Stanik Juraj , Kiess Wieland , Körner Antje

Background and Objective: Obesity is known to affect pubertal timing. However, existing data are still controversial, observing either delayed or accelerated pubertal onset, especially among boys. Herein, we evaluated pubertal milestones and underlying hormonal changes between lean and obese children.Material and Methods: We examined 13,484 events from 4,855 lean (BMI SDS <1.28) and 1,983 obese (BMI SDS > 1.88) c...

hrp0089fc6.3 | Fat, Metabolism and obesity | ESPE2018

Role of PTEN in the Proliferation and Differentiation of Preadipocytes

Kirstein Anna , Kassner Franziska , Schmid Gordian L. , Handel Norman , Penke Melanie , Kiess Wieland , Garten Antje

Background/aim: The PTEN hamartoma tumor syndrome (PHTS) is an overgrowth syndrome caused mainly by germline mutations in the tumor suppressor PTEN. Patients are predisposed for the development of malignant and benign tumors. Children and adolescents with PHTS frequently develop single or multiple lipomas. PTEN antagonizes the phosphatidylinositide3-kinase/AKT/mechanistic target of rapamycin (PI3K/AKT/mTOR) pathway, which promotes proliferation and differentiation in ...